产品
编 号：F740972
分子式：C19H24N4O3S
分子量：388.48
分子式：C19H24N4O3S
分子量：388.48
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 694466-00-7
产品详情
生物活性：
hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy.
体内研究：
hCAI/II-IN-6 (30-100mg/kg; i.p. once) shows good anticonvulsant effect in vivo.hCAI/II-IN-6 (30 mg/kg; p.o. once) shows anti-MES activity in vivo.Animal Model:Swiss albino mice
Dosage:30 and 100 mg/kg
Administration:Intraperitoneal injection; 30-100 mg/kg once
Result:Provided seizure attenuation and good anticonvulsant effect, and showed an ED50 of 13.7mg/kg in anticonvulsant quantification study.
Animal Model:Wistar albino rats
Dosage:30 mg/kg
Administration:Oral gavage; 30 mg/kg once
Result:Showed anti-MES activity and significant protection from seizures up to 1h of drug administration and action was gone reduced after 1h.
体外研究：
hCAI/II-IN-6 (0-50 μM) inhibits hCA I, hCA II , hCA VII and hCA XII activities with Ki values of 220, 4.9, 6.5 and ＞50000 nM, respectively.
hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy.
体内研究：
hCAI/II-IN-6 (30-100mg/kg; i.p. once) shows good anticonvulsant effect in vivo.hCAI/II-IN-6 (30 mg/kg; p.o. once) shows anti-MES activity in vivo.Animal Model:Swiss albino mice
Dosage:30 and 100 mg/kg
Administration:Intraperitoneal injection; 30-100 mg/kg once
Result:Provided seizure attenuation and good anticonvulsant effect, and showed an ED50 of 13.7mg/kg in anticonvulsant quantification study.
Animal Model:Wistar albino rats
Dosage:30 mg/kg
Administration:Oral gavage; 30 mg/kg once
Result:Showed anti-MES activity and significant protection from seizures up to 1h of drug administration and action was gone reduced after 1h.
体外研究：
hCAI/II-IN-6 (0-50 μM) inhibits hCA I, hCA II , hCA VII and hCA XII activities with Ki values of 220, 4.9, 6.5 and ＞50000 nM, respectively.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备